FDA Approves Myqorzo for Symptomatic Obstructive Hypertrophic Cardiomyopathy
MONDAY, Jan. 5, 2026-- The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).Myqorzo is a cardiac myosin inhibitor that directly addresses...
Read more »
Pharmaceutical news
Guidance Updated for Laboratory Testing for Drugs of Misuse in ED
Young Adults With IBD Face Health Care Access Challenges, Financial Burden
Maternal Flu, Tdap Shots May Lower Rates of Infant Hospitalization, ED Visits
Breastfeeding Linked to Lower Odds of Depression, Anxiety
Intake of Preservatives Linked to Increased Cancer Incidence
Nutritional Guidance Lacking for Adults Receiving Semaglutide, Tirzepatide
Multimodal Sleep Foundation Model Can Predict Risk for 130 Conditions
Adverse Prenatal Exposures Linked to Alterations in Psychopathology
Benefit of Retention on MOUD Treatment Lasts for at Least Four Years
RFK Jr. Says Fewer Flu Vaccines for Kids May Be a 'Better Thing'
Weight Often Returns After Stopping Ozempic, Wegovy, Study Finds
Clonal Hematopoiesis of Indeterminate Potential Linked to CVD Risk
Study Ties Rising Evictions to Higher Gun Violence in Chicago
Tamales Sold in California, Nevada Recalled Over Listeria Risk
